A particulate, modified release barrier coated drug-cation exchange resin complex comprising a core composed of a drug complexed with a pharmaceutically acceptable ion-exchange resin is provided. Methods of making and products containing this coated complex are described.

An oral methylphenidate extended release tablet is described, which can be scored and still retain its extended release profile. The tablet contains a combination of an uncoated methylphenidate - ion exchange resin complex, a barrier coated methylphenidate - ion exchange resin complex -matrix, and an uncomplexed methylphenidate active component. Following administration of a single dose of the extended release methylphenidate chewable tablet, a therapeutically effective amount of methylphenidate is reached in less than about 20 minutes and the composition provides a twelve-hour extended release profile.

A product for oral delivery of nicotine comprising a powder composition of a nicotine source, at least one pH adjusting agent, and at least one filler, contained in a pouch which is permeable to saliva and to components of the powder composition once dissolved in saliva, wherein the composition has a solubility of less than 5 g/100 ml. The invention also relates to a method for preparing said product and also the use of said product.

A method of producing embolic particles includes forming a master batch of embolic particles, wherein the master batch of particles includes a plurality of negatively charged loading sites. The method also includes modifying the master batch of particles to form an activated batch of particles by reacting the master patch of particles with a bridging agent. The activated batch of particles includes a plurality of activated loading sites configured to bond to a negatively charged drug.

An oral methylphenidate extended release tablet is described, which can be scored and still retain its extended release profile. The tablet contains a combination of an uncoated methylphenidate-ion exchange resin complex, a barrier coated methylphenidate-ion exchange resin complex-matrix, and an uncomplexed methylphenidate active component. Following administration of a single dose of the extended release methylphenidate chewable tablet, a therapeutically effective amount of methylphenidate is reached in less than about 20 minutes and the composition provides a twelve-hour extended release profile.

The present invention relates to extended-release suspension composition. The present invention specifically relates to extended-release suspension composition comprising active ingredient and pharmaceutically acceptable excipients, wherein said composition is in the form of powder for suspension or a ready to use suspension. The present invention specifically relates to extended-release suspension composition comprising active ingredient and pharmaceutically acceptable excipients, wherein said composition is devoid of uncoated active ingredient-ion exchange resin complex portion and polyvinyl acetate. The present invention also relates to extended-release suspension composition comprising one or more functional barrier coatings on active ingredient-ion exchange resin complex, wherein said functional barrier coatings comprises hypromellose and/or talc.

The present disclosure relates to a method of preparing a thin film composite layer immobilizing vesicles incorporating a transmembrane protein on a porous substrate membrane, comprising providing an aqueous solution comprising the vesicles and a di-amine or tri-amine compound, covering the surface of a porous support membrane with the aqueous solution, applying a hydrophobic solution comprising an acyl halide compound, and allowing the aqueous solution and the hydrophobic solution to perform an interfacial polymerization reaction to form the thin film composite layer.

The present invention relates to oral extended release composition, comprising memantine or its pharmaceutically acceptable salt as an active ingredient, resin complexation ingredient, release retardant, extended release coating system and the composition further comprising diluents, viscosity increasing agents, glidants, sweeteners, stabilizing agents, preservatives and other pharmaceutically acceptable excipients, wherein the drug-resin complex and drug-resin complex matrix particulates and coated drug-resin complex particulates have the specific particle size range. The present invention also relates to a process for the preparation of memantine or its salt oral extended release composition comprising the steps of drug-resin complexation, matrix resinate/particulates preparation process followed by extended release coating. The present invention also relates to oral extended release composition comprising memantine or its pharmaceutically acceptable salt as an active ingredient and pharmaceutically acceptable excipients using extended release resin-complexation technology, further comprising additional active ingredient is in its immediate release form.

The invention relates to dosage forms that provide prolonged therapy. In particular, the invention relates to dosage forms including various pluralities of drug-containing resin particles. The invention also relates to methods of making these dosage forms and methods of treating using these dosage forms.

The invention proposes a polymer solution for visco-supplementation. The polymer solution contains at least one at least partially water-soluble polysaccharide or polysaccharide derivative, one water-soluble alkali salt or alkaline earth salt of polystyrene sulfonic acid, and water, whereby the polymer solution is clear to the eye. Moreover, the invention describes a method for sterilisation of the polymer solution. This method is characterised in that a mixture of at least one at least partially water-soluble polysaccharide or polysaccharide derivative, one water-soluble alkali salt or alkaline earth salt of polystyrene sulfonic acid, and water is mixed with at least 0.5 wt. % propiolactone, and in that the polymer solution is stored at room temperature for at least 24 hours.